Main Article Content
Objective: Inflammatory bowel disease encompasses two major form: Crohn's disease and ulcerative colitis. The Crohn's Disease Activity Index is used to determine the severity of disease activity in patients with Crohn's disease. On the other hand, the Truelove-Witts activity index is used to determine the severity of disease activity in patients with ulcerative colitis. Adalimumab and infliximab are biological agents used in the treatment of patients with inflammatory bowel disease. The aim of this study is to conduct a retrospective evaluation regarding the response to adalimumab and infliximab treatment in patients with inflammatory bowel disease.
Material and Methods: The data of the patients who were over the age of 18, diagnosed with inflammatory bowel disease, and followed up in the Gastroenterology Clinic and Outpatient Clinic of Firat University Hospital between January 2008-April 2019 were assessed. Eighty patients who received adalimumab and infliximab treatment regularly for at least 4 weeks were included in the study.
Results: The Crohn's Disease Activity Index of patients who were diagnosed with Crohn's disease, and received adalimumab and infliximab treatment was compared, and it was found that it was significantly lower after the treatment (p <0.05). Truelove and Witts Activity Index of patients who were diagnosed with Crohn's disease, and received adalimumab and infliximab treatment were compared before and after the treatment, and it was found that it was significantly lower after the treatment (p <0.05).
Conclusion: The results showed that the recovery rate was %83,3 in crohn's disease and %84,6 in ulcerative colitis patients. Adalimumab and infliximab treatment was effective on the healing of active disease in patients with inflammatory bowel disease. It was also concluded that although the safety of adalimumab and infliximab was high, but few allergy, lymphadenopathy, and leukopenia side effects were observed.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Papadakis MA, Mcphee SJ (eds), Lange Güncel Tıbbi Tanı ve Tedavi. Kaya M, Uçmak F, Ekin N, (Çeviren) s.634-645. Ankara, Akademisyen Tıp Kitabevi, 2016.
Biroulet PL, Panés J, Sandborn WJ. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016; 14: 348-354.
Pace JL, Siegel CA. Beyond disease activity to overall disease severity in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2017; 2: 624-626.
Magro F, Gionchetti P, Eliakim R. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
Duijvestein M, Battat R, Casteele VN. Novel therapies and treatment strategies for patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2018; 16: 129–146.
Qin G, Tu J, Liu L. Serum albumin and C-reactive protein/albumin ratio are useful biomarkers of crohn's disease activity. Med Sci Monit 2016; 22: 4393-4400.
Jain S, Kedia S, Bopanna S. Are truelove and witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intest Res 2018; 16: 69–74.
Chaparro M, Verreth A, Lobaton T. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol 2018; 113: 396–403.
Gomollón F, Dignass A, Annese V. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017; 11: 3-25.
Laharie D, Bourreille A, Branche J. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018; 67: 237-243.
Colombel JF, Sandborn WJ, Rutgeerts P. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
Choi CH, Song ID, Chang SK. Efficacy and safety of infliximab therapy and predictors of response in Korean patients with Crohn's disease: A nationwide, multicenter study. Yonsei Med J 2016; 57: 1376–1385.
Hanauer SB, Sandborn WJ, Rutgeerts P. Human anti-tumor necrosis factor monoclonal antibody in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–333.
Sandborn WJ, Hanauer SB, Rutgeerts P. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–1239.
Sandborn WJ, Rutgeerts P, Enns R. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829–838.
Rutgeerts P, Assche VG, Sandborn WJ. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial Gastroenterology 2012; 142: 1102–1111.
Panaccione R, Sandborn WJ, Haens GD. Clinical benefit of long-term adalimumab treatment in patients with Crohn's disease following loss of response or intolerance to infliximab: 96-week efficacy data from GAIN/ADHERE trials. J Crohn's Colitis 2018; 12: 930–938.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876–885.
Panaccione R, Löfberg R, Rutgeerts P. Efficacy and safety of adalimumab by disease duration: analysis of pooled data from Crohn's disease studies. J Crohn's Colitis 2019: 13; 725–734.
Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-790.
Tursi A, Elisei W, Picchio M. Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy. Ann Gastroenterol 2014; 27: 369–373.
Reinisch W, Colombel JF, Haens G. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease. J Crohns Colitis 2017; 11: 425-434.
Osterman MT, Haynes K, Delzell E. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 811-817.
Louis E, Mary JY, Massouille VG. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
Torres J, Boyapati RK, Kennedy NA. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015; 149: 1716-1730.
Qiu Y, Mao R, Chen BL. Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1359-1372.
Lemaitre M, Kirchgesner J, Rudnichi A. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017; 318: 1679-1686.
Hamzaoglu H, Cooper J, Alsahli M. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis 2010, 16: 2109-2116.
Menter A, Thaçi D, Papp KA. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 2015; 73: 410-419.